Your Article Summary
See Latest ArticlesComparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae
Clinical Therapeutics, 01/18/08
Noreddin AM et al. - Based on these simulations, garenoxacin 400 mg QD, gemifloxacin 320 mg QD, and moxifloxacin 400 mg QD appeared likely to achieve target serum and ELF concentrations against S pneumoniae in hospitalized patients with CAP, with a low potential to select for resistance
Related Articles
Streptococcus pneumoniae-associated haemolytic uremic syndrome following influenza A virus infection
European Journal of Pediatrics, 11/17/09
Relevance Score: 69%
First Report of Putative Streptococcus pneumoniae Serotype 6D among Nasopharyngeal Isolates from Fijian Children
The Journal of Infectious Diseases, 10/14/09
Relevance Score: 68%
Impaired C3b/iC3b deposition on Streptococcus pneumoniae in serum from patients with systemic lupus erythematosus
Rheumatology, 10/02/09
Relevance Score: 67%
EstA protein, a novel virulence factor of Streptococcus pneumoniae, induces nitric oxide and pro-inflammatory cytokine production in RAW 264.7 macrophages through NF-kB/MAPK
Microbial Pathogenesis, 11/06/09
Relevance Score: 66%
Xylitol and capsular gene expression in Streptococcus pneumoniae
Journal of Medical Microbiology, 10/21/09
Relevance Score: 66%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Temporal Reduction of HIV Type 1 Viral Load in Breast Milk by Single-Dose Nevirapine during Prevention of MTCT
AIDS Research and Human Retroviruses, 12/18/09
Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
Therapeutics and Clinical Risk Management, 12/18/09
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
Clinical Pharmacokinetics, 12/18/09